5 of Last Week's Biggest Losers
There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
|Jan. 20||Weekly Loss||My Watchlist|
|Columbia Labs (NAS: CBRX)||$1.58||(34%)||Add|
|North American Palladium (ASE: PAL)||$2.34||(24%)||Add|
|Achillion Pharmaceuticals (NAS: ACHN)||$9.47||(23%)||Add|
|Kinross Gold (NYS: KGC)||$10.21||(19%)||Add|
|Complete Genomics (NAS: GNOM)||$2.39||(16%)||Add|
Columbia Labs was the market's biggest loser, shedding more than a third of its value. The FDA advisory committee decided not to recommend the approval of Columbia's vaginal gel in reducing the risk of preterm birth.
North American Palladium slipped after the palladium and gold producer issued uninspiring guidance. The company will also be suspending operations at its Sleeping Giant mine.
Achillion called in sick after an article blasted the prospects of the company's experimental hepatitis C drug.
Kinross Gold wasn't shining after the miner revealed that construction of its Tasiast mine in Africa would be delayed for six to nine months.
Complete Genomics was one of the prior week's biggest losers after an Oppenheimer analyst downgrade. The genetics specialist continued its slide into last week.
It was a rough week for these five stocks. If you want to shake yesterday's losers and ride tomorrow's winners, a new special report reveals Motley Fool's top stock for 2012. It's free, but only for a limited time, so check it out now.
At the time this article was published Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of theRule Breakersnewsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.